Clinical Investigation of the MiStent Drug Eluting Stent (DES) in Coronary Artery Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

184

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

June 30, 2012

Study Completion Date

August 31, 2016

Conditions
Coronary Artery Disease
Interventions
DEVICE

MiStent DES

The MiStent is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).

DEVICE

Endeavor DES

The Endeavor is a device/drug combination comprised of two components; a stent and a drug product (everolimus within a durable polymer coating).

Trial Locations (28)

Unknown

Cardiovascular Center, Aalst

Antwerp Hospital, ZNA Middelheim, Antwerp

Brussels University Hospital, Brussels

Ziekenhuis Oost-Limburg, Genk

Virga Jesse Ziekenhuis, Hasselt

KUL Cardiology Gasthuisberg, Leuven

Jacques Cartier Hospital, Massy

Claude Galien Hospital, Quincy

Clinique Pasteur, Toulouse

OLV, Amsterdam

St. Antonius Ziekenhuis, Nieuwegein

TweeSteden Ziekenhuis, Tilburg

UMC Utrecht, Utrecht

Hospital Weezenlanden, Zwolle

Auckland City Hospital, Auckland

Mercy Angiography Unit, Auckland

Christchurch Hospital, Christchurch

Dunedin Hospital, Dunedin

Wellington Hospital, Wellington

Sahlgrenska University Hospital, Gothenburg

Orebro University Hospital, Örebro

Royal Sussex Hosp, Brighton

Papworth Hospital, Cambridge

Guy's & St. Thomas', London

Royal Brompton, London

University Hospital South Manchester, Manchester

Norfolk/Norwich UHosp, Norwich

Southampton UHT, Southampton

Sponsors
All Listed Sponsors
lead

Micell Technologies

INDUSTRY

NCT01294748 - Clinical Investigation of the MiStent Drug Eluting Stent (DES) in Coronary Artery Disease | Biotech Hunter | Biotech Hunter